ABSTRACT
Lung cancer patients suffer a 5-year survival of 15% despite advances in chemotherapy, radiation therapy and surgery, and the poor prognosis for most patients persists. This has led to a search for new treatment paradigms, more and more focussed on early diagnosis and clinical and chemoprevention trials based on increased knowledge of biology of preneoplastic lesions.1
